Clinical Trial Update: Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating grape seed extract as an anti-oligomerization agent in Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Grape Seed Extract (grape seed extract)

Snippet

Sponsor: Hillel Grossman | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED